PAVmed Ebitda from 2010 to 2024

PAVMZ Stock  USD 0.01  0.0001  0.66%   
PAVmed Series EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA is likely to outpace its year average in 2024. During the period from 2010 to 2024, PAVmed Series EBITDA regression line of annual values had significance of  0.00005 and arithmetic mean of (26,249,342). View All Fundamentals
 
EBITDA  
First Reported
2015-03-31
Previous Quarter
-14.6 M
Current Value
61 M
Quarterly Volatility
13.7 M
 
Yuan Drop
 
Covid
Check PAVmed Series financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PAVmed Series' main balance sheet or income statement drivers, such as Interest Expense of 559.5 K, Selling General Administrative of 32.5 M or Other Operating Expenses of 74.8 M, as well as many indicators such as Price To Sales Ratio of 11.54, Dividend Yield of 3.0E-4 or Days Sales Outstanding of 14.05. PAVmed financial statements analysis is a perfect complement when working with PAVmed Series Valuation or Volatility modules.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Latest PAVmed Series' Ebitda Growth Pattern

Below is the plot of the Ebitda of PAVmed Series Z over the last few years. It is PAVmed Series' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PAVmed Series' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

PAVmed Ebitda Regression Statistics

Arithmetic Mean(26,249,342)
Coefficient Of Variation(126.46)
Mean Deviation27,676,559
Median(11,151,294)
Standard Deviation33,195,030
Sample Variance1101.9T
Range97.6M
R-Value(0.85)
Mean Square Error320.7T
R-Squared0.73
Significance0.00005
Slope(6,340,958)
Total Sum of Squares15426.7T

PAVmed Ebitda History

2024-72 M
2023-75.7 M
2022-99.4 M
2021-55.9 M
2020-35.8 M
2019-15.4 M
2018-12.1 M

About PAVmed Series Financial Statements

PAVmed Series investors use historical fundamental indicators, such as PAVmed Series' Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in PAVmed Series. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-75.7 M-72 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for PAVmed Stock Analysis

When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.